TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07738939: IKS04 Regimen in Advanced Solid Tumors That Express CA242

Sponsor: Iksuda Therapeutics Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07738939 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07738939 Rescue Dossier →